Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gram-negative enteric bacterial surface antigens represent a broad category of molecular structures located on the outer membrane of bacteria within the Enterobacteriaceae family and related genera. These include lipopolysaccharides (LPS), which consist of Lipid A (an endotoxin), a core polysaccharide, and the highly variable O-antigen, as well as flagellar (H) and capsular (K) antigens. These molecules are critical for the structural integrity of the bacteria and play a central role in host-pathogen interactions, often serving as primary targets for the host's immune system during an infection. In a therapeutic context, these antigens are utilized in the development of polyvalent bacterial lysates and vaccines designed to boost mucosal immunity and prevent recurrent infections, such as urinary or respiratory tract infections. Additionally, they have been the focus of monoclonal antibody development aimed at neutralizing endotoxins or promoting bacterial clearance in cases of severe sepsis, although many such targeted therapies have faced significant challenges in clinical efficacy. (Sources: StatPearls: Gram Negative Bacteria; PubMed: PMCID PMC7150055; NIH: Bacterial Antigenic Structures).
Stimulation of the innate and adaptive immune systems through exposure to bacterial components, or direct neutralization and opsonization by monoclonal antibodies to facilitate phagocytosis and clearance.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative enteric bacterial surface antigens.